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Abstract
Background: Sputum and blood eosinophil counts predict corticosteroid effects in COPD patients. Bacterial
infection causes increased airway neutrophilic inflammation. The relationship of eosinophil counts with airway
bacterial load in COPD patients is uncertain. We tested the hypothesis that bacterial load and eosinophil counts are
inversely related.
Methods: COPD patients were seen at stable state and exacerbation onset. Sputum was processed for quantitative
polymerase chain reaction detection of the potentially pathogenic microorganisms (PPM) H. influenzae, M.
catarrhalis and S. pneumoniae. PPM positive was defined as total load ≥1 × 104copies/ml. Sputum and whole blood
were analysed for differential cell counts.
Results: At baseline, bacterial counts were not related to blood eosinophils, but sputum eosinophil % was
significantly lower in patients with PPM positive compared to PPM negative samples (medians: 0.5% vs. 1.25%
respectively, p = 0.01). Patients with PPM positive samples during an exacerbation had significantly lower blood
eosinophil counts at exacerbation compared to baseline (medians: 0.17 × 109/L vs. 0.23 × 109/L respectively, p = 0.
008), while no blood eosinophil change was observed with PPM negative samples.
Conclusions: These findings indicate an inverse relationship between bacterial infection and eosinophil counts.
Bacterial infection may influence corticosteroid responsiveness by altering the profile of neutrophilic and
eosinophilic inflammation.
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Background
COPD is a heterogeneous condition, composed of differ-
ent clinical and pathophysiological components that vary
both in presence and severity between patients [1]. This
heterogeneity causes variability in the responses to
pharmacological treatments. Biomarkers that predict
treatment responses to anti-inflammatory drugs may be
useful for optimising the benefit versus risk ratio.
Sputum eosinophil counts in stable COPD patients
predict the clinical response to corticosteroids [2, 3].
However, measuring sputum eosinophils is time con-
suming, and some patients do not provide adequate
samples for analysis. Blood eosinophil measurements are
more practical, and appear to be a surrogate biomarker
for sputum eosinophils as these measurements show a
degree of correlation within the same individual, both in
stable COPD patients and during exacerbations [4–7].
Retrospective analysis of COPD clinical trials have
shown that higher blood eosinophil counts predict a
greater reduction in exacerbation rates with inhaled
corticosteroid/long acting beta agonist (ICS/LABA)
combinations compared to LABA [8–10]. Furthermore,
oral corticosteroid treatment during exacerbations has a
greater effect in COPD patients with higher blood
eosinophil counts [11].
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Chronic bacterial infection in COPD patients causes
greater neutrophilic inflammation in the lungs [12–14].
Neutrophilic lung inflammation responds poorly to
corticosteroids [15–17], implicating bacterial infection as
a potential cause of corticosteroid insensitivity in COPD
patients. The relationship between bacterial infection
and eosinophil counts is not established in COPD. There
may be an inverse relationship between these parame-
ters, as blood eosinophil counts are known to be
reduced during severe bacterial infection [18, 19]. The
existence of such an inverse relationship would suggest
that the interaction between bacterial infection and eosin-
ophils determines the corticosteroid response in COPD
patients.
The primary aim of the analysis reported here using
data from the COPDMAP cohort was to test the hypoth-
esis that the bacterial load and eosinophil counts are
inversely related in COPD patients. We investigated the
relationship between eosinophil counts (in the blood
and sputum) and the bacterial load in the stable state
and during exacerbations in COPD patients.
Methods
Subjects
COPD patients aged ≥ 40 years were recruited at 3 sites
(Manchester, Leicester and London) and enrolled into
the COPDMAP prospective observational cohort study
(www.copdmap.org). Patients had a physician diagnosis
of COPD, post-bronchodilator forced expiratory volume
in 1 s (FEV1)/forced vital capacity (FVC) ratio <0.7, ≥10
pack year smoking history and no previous asthma diag-
nosis. The patients included in this analysis were those
who provided a blood sample for eosinophil analysis and
a sputum sample for bacterial quantification at the base-
line visit. All patients provided written informed consent
using protocols approved by the local Ethics Committees
(11/L0/1630; 10/H/1003/108; 07/H0406/157).
Additional methods are in the online supplement
(Additional file 1).
Study design
Patients were seen at baseline and at exacerbation onset.
Symptoms were assessed using the modified MRC Scale
(mMRC) and the COPD assessment test (CAT). Health
related quality of life using the St George’s Respiratory
Questionnaire (SGRQ-C) and fat free mass index (FFMI)
were assessed. Lung function measurements and 6 min
walk test (6MWT) were performed according to guide-
lines [20, 21]. Spontaneous and/or induced sputum was
obtained as previously described [22] and blood samples
sent to local hospital laboratories.
Patients contacted the research team if they experi-
enced a change in symptoms consistent with an acute
exacerbation. Daily diary cards were used. Patients were
assessed by a clinician and exacerbations defined as in
increase in two respiratory symptoms (with at least one
major symptom) for two consecutive days [23]. Blood
and sputum sampling were performed prior to any
systemic therapy including treatment with oral cortico-
steroids and/or antibiotics. Samples from the first
exacerbation event per patient were used in this analysis.
Sputum and blood analysis
All patients attempted to produce a spontaneous sample
at baseline and exacerbation. A sputum induction was
attempted (safety permitting) if an insufficient spontan-
eous sample was produced. Spontaneous or induced
sputum was processed for quantitative polymerase chain
reaction (qPCR) detection of the common respiratory
potentially pathogenic microorganisms (PPM) H. influ-
enzae, M.catarrhalis and S. pneumoniae and for human
rhinovirus (RV) as previously described [24, 25]. Patients
were categorised as PPM positive if the total load was
above 1 × 104copies/ml or RV positive if the load was
greater than 1 × 101copies/ml [26, 27]. Sputum was also
processed for differential cell counts (Additional file 2:
Figure S1) [28]. However, small sputum samples (mini-
mum weight of approximately 0.075 g) were preferen-
tially processed for qPCR analysis only. Whole blood
was analysed for differential leukocyte count and the
blood eosinophil count measured at baseline and exacer-
bation were used in this analysis.
Statistical analysis
Statistical analysis for non-parametric data was performed
using; Wilcoxon signed rank test for within individual com-
parison or the Mann–Whitney U test for between group
comparison and chi-square test for categorical variables.
Receiver operating characteristics (ROC) curves determined
if blood eosinophil counts predict a sputum eosinophil
count of ≥3%. Spearman’s correlation test assessed associa-
tions between variables. P < 0.05 was considered statistically
significant. Analyses were performed using GraphPad Prism
version 6.00 (San Diego, USA).
Results
Stable state microbiology and eosinophils
Blood eosinophil counts
One hundred sixty-eight patients had a blood eosinophil
and sputum qPCR bacterial measurement at baseline.
The demography of this population is shown in Table 1;
the mean post-bronchodilator FEV1 was approximately
57% predicted, with a median exacerbation rate in the
previous year of 1, and mean CAT and SGRQ scores of
18.7 and 47.8 respectively. 52% of patients had PPM
positive samples (defined by a threshold value of ≥1 ×
104). There were no differences in the blood eosinophil
count (medians: 0.21 × 109/L vs. 0,18 × 109/L, p = 0.50),
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sputum cells counts (all p > 0.05) and total bacterial load
(medians: 3.55 × 104 vs.5.38 × 104, p = 0.52) between ICS
users and non-users respectively.
There were no significant associations between the
blood eosinophil count and bacterial load (Fig. 1a), and
no difference in bacterial load using different blood eo-
sinophil threshold values i.e. ≥ and <150 cells/μl (Fig. 2a),
2% or 300 cell/μl (not shown). Additionally, there were
no differences in blood eosinophil counts between pa-
tients with PPM positive and PPM negative samples
(Fig. 2b).
Sputum eosinophil counts
Ninety-four of the 168 patients produced a sufficient
sputum sample for differential cell count analysis; of
which 75 and 19 were from spontaneous and induced
samples respectively. Total cell count (x106/g) in the
spontaneous samples were lower compared to induced
samples (medians: 2.75 vs. 6.59 respectively, p = 0.003),
but no differences were observed for sputum % differen-
tial counts including sputum eosinophil % (medians 0.75
vs. 0.6 respectively, p = 0.82).
Figure 2c shows that patients with a sputum eosino-
phil count ≥3% had a significantly lower bacterial load
compared to those with a sputum eosinophil <3% (p =
0.046). The inflammatory cell profiles of the patients
with sputum eosinophil count <3% and ≥3% are pre-
sented in Table 2; there was a higher neutrophil percent-
age (medians 80.1% vs. 68.4% respectively) and lower
absolute eosinophil cell count (medians 0.2 × 106/g ver-
sus 0.0 × 106/g respectively) in the former group.
The sputum eosinophil % was significantly lower in
patients with PPM positive samples compared to PPM
negative samples (medians: 0.5% vs. 1.25%, p = 0.01,
Fig. 2d). Sputum eosinophil % was inversely correlated
with bacterial load (rho = −0.26, p < 0.01, Fig. 1b). This
association was not evident with the sputum eosinophil
absolute count (p = 0.5). There was a significant positive
correlation between the bacterial load and both sputum
neutrophil % and absolute cell count (rho = 0.25, p =
0.02 and rho = 0.22, p = 0.04 respectively, Fig. 3).
Exacerbation microbiology and eosinophils
There were 109 exacerbation events that had blood eo-
sinophil counts at both baseline and exacerbation, and
qPCR bacterial counts at exacerbation. The exacerba-
tions occurred a mean 171 days after the baseline visit;
78 exacerbations were PPM positive and 31 were PPM
negative. A subset of 70 patients also had a baseline
qPCR bacterial count. Sputum eosinophil % counts at
baseline and exacerbation were available in 30 of these
patients; 22 were PPM positive and 8 were PPM negative
(Additional file 3: Figure S2 shows a summary of the
number of patients with blood/sputum eosinophil
counts and qPCR data at exacerbation alone, or coupled
to baseline measurements).
The differences in blood counts, sputum counts and
bacterial load between baseline and exacerbation in the
whole population are presented in Table 3. White blood
Table 1 Baseline demographics of the patients enrolled onto
the study
Characteristics n
Age, yrs 168 69.8 (8.1)
Gender, (% Male) 168 74
Current Smoker, (%) 168 32
Inhaled steroid use (%) 168 86
Inhaled steroid dose (μg) (BDP equivalent) 168 1000 [200–2000]
LABA use (%) 168 88
LAMA use (%) 168 78
Pack Years 168 47.0 [10.0–220.0]
BMI (kg/m2) 168 26.2 [18.0–45.0]
FFMI (kg/m2) 159 17.8 (3.5)
Chronic Bronchitis (%) 164 73
Exacerbation rate (prior study entry) 168 1.0 [0.0–15.0]
SGRQ total 162 47.8 (18.4)
mMRC score 145 2.0 [1.0–4.0]
CAT score 165 18.7 (7.1)
6MWD 132 380.9 (109.4)
KCO, % 119 75.4 (27.0)
Pre FEV1 (L) 104 1.5 (0.6
Pre FEV1% 104 55.7 (19.9)
Pre FVC (L) 104 3.0 (0.9)
Pre FEV1/FVC 104 0.5 (0.1)
Post FEV1 (L) 168 1.5 (0.6)
Post FEV1% 168 56.8 (18.9)
Post FVC (L) 168 3.0 (0.9)
Post FEV1/FVC 168 0.5 (0.1)
Reversibility % 105 7.2 [−13.0–32.5]
Reversibility ml 105 100 [−180–420]
Sputum Total Cell Count x106/g 90 3.7 [0.2–84.6]
Sputum Neutrophil % 94 76.0 [1.0–99.3]
Sputum Eosinophil % 94 0.8 [0.0–13.2]
Sputum Neutrophil cell count x106/g 90 2.5 [0.0–82.4]
Sputum Eosinophil cell count x106/g 90 0.03 [0.0–0.5]
PPM positive (≥1 × 104 copies/ml), % 168 52
Summaries are presented as mean (SD), median [Range] and percentages
as appropriate
Definitions of abbreviations: BDP Beclometasone dipropionate equivalent,
LABA Long Acting Beta Agonist, LAMA Long Acting muscarinic antagonist, BMI
Body Mass Index, FFMI, Fat Free Mass Index; SGRQ St George’s Respiratory
Questionnaire, mMRC modified Medical Research Council, CAT COPD
Assessment Test, 6MWD 6 min walk test, FEV1 Forced Expired Volume in first
second, FVC Forced vital capacity, PPM Potentially pathogenic microorganism,
Pre Pre bronchodilator, Post Post bronchodilator
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cell count (WBC), blood neutrophil and monocyte counts
were significantly increased at exacerbation, while there was
no difference for the blood eosinophil count. Bacterial load,
total sputum cell count (x106/g) and the absolute and %
sputum neutrophil count were higher at exacerbation. The
absolute and % sputum macrophage counts and sputum eo-
sinophil % were significantly lower at exacerbation.
Blood eosinophil counts
Table 4 presents a comparison of the blood counts be-
tween baseline and exacerbation for the PPM positive and
negative groups. Patients with PPM positive samples
(using a threshold value of ≥1 × 104) during an exacerba-
tion had significantly lower blood eosinophil counts at ex-
acerbation compared to baseline (medians: 0.17 × 109/L
vs. 0.23 × 109/L respectively, p = 0.008, Fig. 4). There was
no change in the blood eosinophil count at exacerbation
compared to baseline in patients with PPM negative sam-
ples at exacerbation (medians: 0.23 × 109/L vs. 0.22 × 109/
L respectively). The median decrease in blood eosinophil
count between the baseline and exacerbation visit was sig-
nificantly different in PPM positive compared to PPM
a b
Fig. 1 The correlation between bacterial load and a blood eosinophil count and b sputum eosinophil % at baseline
a b
c d
Fig. 2 The relationship between eosinophils and bacterial load at baseline; a the bacterial load in patients with blood eosinophil ≥ 150 cells/μl
and < 150 cells/μl, b the blood eosinophil count between PPM negative and PPM positive groups, c the bacterial load in patients with sputum
eosinophil count ≥ 3% and < 3%, d the sputum eosinophil % between PPM negative and PPM positive groups
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negative patients (medians: −0.02 × 109/L vs. 0.04 × 109/L
respectively, p = 0.004, Fig. 4). A similar pattern was ob-
served using a PPM threshold of ≥1 × 106 at exacerbation
(Additional file 4: Figure S3).
The proportion of individuals with a decrease in blood
eosinophil counts at exacerbation from baseline was sig-
nificantly higher in PPM positive patients compared to
PPM negative patients (53% vs 29%, p = 0.02). 4/78 (5%)
of the PPM positive and 1/31 (3%) of the PPM negative
patients had blood eosinopenia (counts ≤0.04 × 109/L).
A significant increase in the blood neutrophil count
was observed at exacerbation compared to baseline in
patients with PPM positive (medians: 6.13 × 109/L vs.
4.95 × 109/L respectively, p < 0.0001) and negative sam-
ples (5.50 × 109/L vs 4.38 × 109/L respectively, p = 0.004)
during exacerbation (Table 4). There was no significant
difference in the median change between the 2 groups
(p > 0.99). In addition, the total WBC and blood mono-
cyte count were significantly increased at exacerbation
compared to baseline in both the PPM positive and
negative groups (Table 4).
Seventy-five of the 109 patients had rhinovirus load
measured at exacerbation; 16 were rhinovirus positive
and 59 were rhinovirus negative. 75% and 71% of the
rhinovirus positive and negative samples were PPM posi-
tive respectively. There were no changes in blood eosino-
phil counts between the baseline and exacerbation visit in
the rhinovirus positive (medians: 0.26 vs. 0.20 respectively,
p = 0.87) and negative (medians: 0.22 vs. 0.17 respectively,
p = 0.34) groups (Additional file 5: Table S1).
Sputum eosinophil counts
Sputum eosinophil % decreased significantly at exacer-
bation compared to baseline in patients who were
PPM positive (medians: 0.23% vs. 0.75% respectively,
p = 0.046 & Fig. 5). No significant change was ob-
served in patients who were PPM negative at exacer-
bation (Fig. 5). The comparison of the eosinophil
count change from baseline to exacerbation revealed
no difference between PPM positive and PPM negative
patients. When repeating the analysis using sputum
Table 2 PPM load and sputum inflammatory cell counts in patients with and without eosinophilic inflammation
Sputum ≥3% (n = 18) <3% (n = 76) p value
PPM load (copies/ml) 0.0 [0.0–8.2 × 107] 2.7 × 105 [0–4.9 × 108] 0.046
Neutrophil % 68.4 [7.0–89.8] 80.1 [1.0–99.3] 0.04
Macrophage% 17.4 [2.9–85.5] 15.3 [0.5–88.5] 0.27
Eosinophil % 5.9 [3.0–13.2] 0.5 [0.0–3.0] <0.0001
Lymphocyte % 0.0 [0.0–3.0] 0.0 [0.0–6.0] 0.16
Epithelial % 4.0 [0.5–33.0] 2.5 [0.0–89.3] 0.26
Total cell count x106/g 4.0 [0.2–9.9] 3.4 [0.2–84.6] 0.62
Neutrophil cell count x106/g 2.1 [0.0–7.7] 2.5 (0.0–82.4] 0.38
Macrophage cell count x106/g 0.7 [0.0–2.3] 0.5 [0.1–4.2] 0.68
Eosinophil cell count x106/g 0.2 [0.0–0.5] 0.0 [0.0–0.4] <0.0001
Lymphocyte cell count x106/g 0.0 [0.0–0.1] 0.0 [0.0–0.3] 0.13
Epithelial cell count x106/g 0.1 [0.0–0.6] 0.10 [0.00–2.3] 0.46
Summaries are presented as median [Range]
Fig. 3 The correlation between bacterial load and both sputum neutrophil % and absolute count at baseline
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neutrophil % in both the PPM positive and negative
groups, we observed a numerical but non-significant
increase in both groups (Additional file 6: Figure S4).
Comparisons of the other sputum cell counts are pre-
sented further in Table 4.
Relationship between blood and sputum eosinophils
One hundred ten patients had both a blood and sputum
eosinophil count available at baseline, while 62 patients
had a blood and sputum eosinophil count available
during their first exacerbation event. The baseline blood
Table 3 Comparison of blood, sputum and bacterial counts between baseline and exacerbation
n Baseline Exacerbation p value
Total white blood cell count (x109/L) 109 7.35 [4.40–15.60] 8.90 [2.80–20.50] <0.0001
Neutrophil blood count (x109/L) 109 4.69 [2.55–12.23] 6.01 [1.42–18.12] <0.0001
Eosinophil blood count (x109/L) 109 0.23 [0.04–0.90] 0.18 [0.00–0.78] 0.22
Lymphocyte blood count (x109/L) 109 1.70 [0.75–4.25] 1.80 [0.44–4.66] 0.133
Monocyte blood count (x109/L) 109 0.57 [0.28–1.41] 0.70 [0.26–1.86] <0.0001
Total Cell count (x106/g) 30 4.07 [0.25–84.56] 8.67 [0.41–154.5] 0.02
Sputum Neutrophil cell count (x106/g) 30 3.34 [0.02–82.44] 7.20 [0.08–151.6] 0.03
Sputum Macrophage cell count (x106/g) 30 0.74 [0.04–4.22] 0.09 [0.00–1.55] <0.0001
Sputum Eosinophil cell count (x106/g) 30 0.06 [0.00–0.52] 0.01 [0.00–3.20] 0.11
Sputum Lymphocyte cell count (x106/g) 30 0.00 [0.00–0.25] 0.00 [0.00–0.09] 0.46
Sputum Epithelial cell count (x106/g) 30 0.19 [0.00–2.32] 0.17 [0.00–0.95] 0.39
Sputum Neutrophil % 30 77.13 [3.00–97.75] 89.00 [5.25–99.25] 0.04
Sputum Macrophage % 30 15.88 [1.50–88.50] 6.75 [0.50–70.25] 0.02
Sputum Eosinophil % 30 0.92 [0.00–12.75] 0.38 [0.00–86.5] 0.03
Sputum Lymphocyte % 30 0.13 [0.00–2.50] 0.00 [0.00–1.00] 0.06
Sputum Epithelial cell % 30 3.94 [0.00–40.00] 2.89 [0.00–54.76] 0.74
Total Bacterial Load (genome copies/ml) 70 2.85 × 103 [0.0–3.69 × 1010] 5.13 × 105 [0.0–6.09 × 108] 0.02
Table 4 Comparison of blood and sputum counts between baseline and exacerbation for PPM positive and PPM negative groups
BLOOD PPM positive n = 78 PPM negative n = 31
Baseline Exacerbation p value Baseline Exacerbation p value
White blood cell count (x109/L) 7.4 [4.4–15.6] 8.9 [2.8–20.5] <0.0001 7.00 [5.03–13.4] 8.90 [4.90–15.40] <0.0001
Neutrophil count (x109/L) 4.95 [2.95–12.23] 6.13 [1.42–18.12] <0.0001 4.38 [2.97–8.29] 5.50 [2.36–10.98] 0.004
Eosinophil blood count (x109/L) 0.23 [0.05–0.90] 0.17 [0.00–0.76] 0.008 0.22 [0.04–0.57] 0.23 [0.02–0.78] 0.08
Lymphocyte blood count (x109/L) 1.70 [0.75–3.67] 1.89 [0.44–4.66] 0.13 1.67 [1.00–4.25] 1.79 [0.50–3.03] 0.69
Monocyte blood count (x109/L) 0.55 [0.28–1.41] 0.68 [0.26–1.87] <0.0001 0.6 [0.4–1.06] 0.77 [0.42–1.43] <0.0001
SPUTUM PPM positive n = 22 PPM negative n = 8
Baseline Exacerbation p value Baseline Exacerbation p value
Total Cell count (x106/g) 5.84 [0.63–84.56] 10.58 [0.41–154.5] 0.14 3.01 [0.25–5.27] 6.51 [0.60–36.67] 0.008
Sputum Neutrophil count (x106/g) 5.14 [0.02–82.44] 9.79 [0.08–151.6] 0.11 0.73 [0.16–3.61] 5.19 [0.19–35.75] 0.05
Sputum Macrophage count (x106/g) 0.74 [0.14–4.22] 0.11 [0.00–1.55] <0.0001 0.74 [0.04–2.16] 0.07 [0.01–0.37] 0.02
Sputum Eosinophil count (x106/g) 0.07 [0.00–0.52] 0.01 [0.00–0.31] 0.09 0.02 [0.01–0.50] 0.03 [0.00–3.17] 0.61
Sputum Lymphocyte count (x106/g) 0.00 [0.00–0.25] 0.00 [0.00–0.27] 0.11 0.00 [0.00–0.01] 0.005 [0.00–0.09] 0.31
Sputum Epithelial count (x106/g) 0.19 [0.00–2.32] 0.16 [0.00–0.84] 0.56 0.20 [0.04–0.30] 0.24 [0.03–0.95] 0.74
Sputum Neutrophil % 84.00 [3.00–97.75] 90.75 [19.00–99.25] 0.21 55.38 [7.00–83.53] 78.00 [5.25–97.5] 0.11
Sputum Macrophage % 11.12 [1.50–88.50] 6.00 [0.50–70.25] 0.28 26.88 [8.82–85.5] 9.00 [1.5–35.5] 0.02
Sputum Eosinophil % 0.75 [0.00–6.98] 0.23 [0.00–2.00] 0.046 1.88 [0.29–12.75] 1.00 [0.00–86.5] 0.38
Sputum Lymphocyte % 0.00 [0.00–0.25] 0.00 [0.00–1.00] 0.35 0.00 [0.00–2.50] 0.13 [0.00–0.25] 0.63
Sputum Epithelial cell % 2.13 [0.00–40.00] 2.13 [0.00–54.76] 0.89 7.68 [1.50–17.50] 5.00 [0.75–11.00] 0.25
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eosinophil % and absolute counts were weakly correlated
with sputum eosinophil % (rho = 0.24, p = 0.01 and rho
= 0.19, p = 0.05 respectively) and baseline blood eosino-
phil % and absolute counts did not predict sputum
eosinophil % (area under the ROC curve (AUC) 0.59, p
= 0.21 and AUC 0.52, p = 0.79 respectively, Fig. 6a). In
contrast, at exacerbation there was a stronger correlation
for blood eosinophil % (rho = 0.41, p = 0.001) and abso-
lute counts (rho = 0.43, p < 0.001) with sputum eosino-
phil %. Both blood eosinophil % and absolute count
were good predictors of sputum eosinophil % at exacer-
bation (AUC 0.80, p = 0.005 and AUC 0.76, p = 0.01 re-
spectively, Fig. 6b).
Discussion
We observed evidence of an inverse relationship be-
tween bacterial infection and eosinophil counts in
COPD. Firstly, sputum eosinophil counts were lower in
COPD patients with bacterial infection in the stable
state. Secondly, COPD patients with bacterial infection
during exacerbations had a significant decrease in the
blood eosinophil absolute count compared to the stable
state, while no blood eosinophil count changes were ob-
served in patients without bacterial infection. These ob-
servations during the stable state and exacerbations
showing an inverse relationship between bacterial infec-
tion and eosinophil counts may be relevant to cortico-
steroid responsiveness in COPD; the increased
corticosteroid responsiveness observed with higher eo-
sinophil counts could be due, at least partly, to lower
levels of bacterial infection..
This inverse relationship between bacterial counts and
blood eosinophils was present during exacerbations but
not in the stable state. This is likely to be due to the
Fig. 4 The blood eosinophil count at baseline and exacerbation in patients defined as PPM positive or PPM negative at exacerbation (PPM threshold
value of 1 × 104). PPM = potentially pathogenic microorganisms. Dotted lines represent median values
Fig. 5 The sputum eosinophil count at baseline and exacerbation in patients defined as PPM positive or PPM negative at exacerbation (PPM threshold
value of 1 × 104). PPM = potentially pathogenic microorganisms. Dotted lines represent median values
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stronger association between blood and sputum eosino-
phils at exacerbation compared to the stable state. Blood
eosinophils have been proposed as a surrogate bio-
marker of sputum eosinophils, but the weak relationship
between these measurements in the stable state, demon-
strated here and in previous studies [6, 7], highlights a
limitation of blood eosinophil counts in this context.
The prevalence of bacterial colonisation at baseline in
our study (52%) was comparable to previously published
studies that used qPCR to detect PPM presence; Bafad-
hel et al., [12] reported a 51% prevalence while, Barker
et al., [26] reported a 77% prevalence. In the stable state,
higher bacterial counts were associated with higher spu-
tum neutrophil % and lower eosinophil %. This relation-
ship between higher sputum bacterial counts and
increased sputum neutrophil % is known [12, 13, 29].
The lower sputum eosinophil % in COPD patients with
bacterial colonisation is partly due to the bacterial driven
increase in absolute and percentage neutrophil counts
causing a lower calculated eosinophil %. However, the
absolute sputum eosinophil count is not dependent on
any calculation involving the neutrophil count, and
we observed that the absolute sputum eosinophil
count was also lower in patients with sputum eosino-
phils <3%, indicating a genuine reduction in eosino-
phil numbers in the airways of patients with higher
bacterial counts.
The inverse relationships between bacterial counts and
sputum eosinophils provide a potential mechanism that
determines corticosteroid responsiveness in COPD pa-
tients. Individuals with lower sputum eosinophil counts
have higher levels of bacterial infection; perhaps the
presence of more bacteria, with associated neutrophilic
inflammation [12–14], contributes to the lower cortico-
steroid response previously reported [16, 17]. Neutrophilic
airway inflammation appears to be poorly responsive to
corticosteroid treatment [15, 17, 30], and the absence of
bacterial inflammation may therefore favour a greater
corticosteroid response through a shift in the balance of
airway inflammation away from neutrophilic inflammation
towards more eosinophilic inflammation.
Previous studies have failed to show a significant
difference in sputum eosinophil % between stable COPD
patients with bacteria present versus those without,
although a numerical decrease in the former group was
observed [12, 26]. Compatible with our results is the
previous finding of a significantly lower level of sputum
CCL13 (an eosinophil associated cytokine) in PPM
positive COPD patients [26].
It has been reported that the effects of oral corticoste-
roids are dependent on the blood eosinophil count dur-
ing COPD exacerbations, with more likelihood of
treatment failure or a longer hospital stay with lower
blood eosinophil counts [11, 31, 32]. The data reported
here show lower eosinophil counts during acute bacter-
ial infections, and it could be inferred that treatment
failure with oral corticosteroids in such cases is related
to the presence of airway bacteria. During exacerbations
both sputum and blood eosinophil measurements
showed similar relationships to bacterial counts. How-
ever, the sputum data were less robust due to smaller
sample size.
Blood neutrophil counts are known to increase during
infection, irrespective of bacterial presence [33]; we ob-
served the same during COPD exacerbations. The de-
crease in blood eosinophil absolute count during
exacerbation cannot be due to the increase in blood neu-
trophil counts for two reasons. First, there was a similar
increase in blood neutrophil counts in both PPM posi-
tive and negative patients; second, we measured blood
eosinophil absolute numbers which are not influenced
by calculations of percentage relative to neutrophils.
In COPD patients hospitalised for exacerbations, blood
eosinopenia is an independent predictor of mortality and
a b
Fig. 6 ROC curves of blood eosinophil counts as a predictor of sputum eosinophilia at a baseline and b exacerbation
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length of stay [34, 35]. The exacerbations in this study
were treated in the outpatient setting (only 3/109 exac-
erbations resulted in hospitalisation). These less severe
events had few cases of eosinopenia (5/109 patients).
Nevertheless, our results demonstrate an effect of airway
bacteria on blood eosinophil counts even in patients
without overt bacterial sepsis. Similarly, blood eosinophil
counts decrease in asthma patients with bacterial infec-
tions [36].
Rhinovirus infection had no effect on blood eosinophil
counts. Experimental rhinovirus infection causes an in-
crease in the airway bacterial load, demonstrating the
complexity of the relationship between virus and bacter-
ial infection during COPD exacerbations [37]. Our re-
sults indicate that bacterial, rather than viral, infection
modulates blood eosinophil counts. However, it is worth
noting that due to insufficient sputum samples being
available, rhinovirus detection was performed in a
smaller proportion of patients (75/109 patients). Conse-
quently, the lack of effect of rhinovirus on eosinophil
counts could potentially be attributed to limited power
in the analysis.
The mechanism responsible for the decrease in eo-
sinophil counts during bacterial infection is unclear. Eo-
sinophils can trigger innate immune responses to
pathogens through the release of extracellular DNA
traps and the expression of specific pattern recognition
receptors including Toll like receptor 4 [38, 39]. Further-
more, eosinophil granule proteins have bactericidal ac-
tivity [40]. A decrease in circulating eosinophils may be
a result of adrenal glucocorticoid stimulation in response
to the stress of bacterial infection or the rapid accumula-
tion of eosinophils at the inflammatory site [41, 42].
A limitation of this study is that we defined a bacteria
positive sample based on the total load of bacteria mea-
sured rather than a species specific count. This was done
to increase statistical power to address the relationship
between eosinophils and the common pathogenic bac-
teria in COPD. However, it is important to note that the
total bacterial load from each bacteria positive sample
had at least one of the three quantified pathogens above
the 1 × 104 threshold used. The presence of other im-
portant bacteria, such as Pseudomonas aeruginosa, was
not assessed using qPCR. Additionally, we cannot dis-
count the possibility of selection bias as a proportion of
our patients failed to provide an adequate, high quality
sputum sample for differential cell count analysis. The
majority of the sputum samples used in our study were
spontaneously produced and although cell viability can
be lower in spontaneous samples [43], we observed no
differences in % sputum counts between spontaneous
and induced samples, including the sputum eosinophil %
count as previously reported [43]. Finally, the majority
of our patients were using ICS, but we found no
difference in sputum or blood cell counts or bacterial
loads due to ICS use. This is in keeping with studies that
have shown no effect of ICS on blood or sputum eosino-
phil counts [2, 44].
Future studies of the effects of ICS during the stable
state could measure sputum (and blood) eosinophil
counts and bacterial loads to test the hypothesis that in-
creased bacterial load associated with reduced sputum
eosinophil counts predicts reduced therapeutic response.
Similar studies using oral corticosteroids during acute
exacerbations measuring blood eosinophil counts and
bacterial loads could test the hypothesis that increased
bacterial load associated with reduced blood eosinophil
counts predicts reduced therapeutic response.
Conclusion
In conclusion, our results show an inverse relationship
between sputum eosinophils and airway bacterial load
during the stable state, while a decrease in blood eosino-
phil counts occurs in COPD exacerbations with bacterial
presence. These inverse relationships between eosinophil
measurements and bacterial counts are potentially im-
portant determinants of individual responses to cortico-
steroid treatment.
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